Source: San Diego Business Journal

VelosBio: Merck Buys VelosBio for $2.75 Billion

BIOTECH: Acquisition Will Strengthen Merck's Oncology Pipeline

Read full article »
VelosBio's Competitors | VelosBio's News | VelosBio's Financials
Stay up-to-date with the latest news on VelosBio
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
David Johnson's photo - Founder & CEO of VelosBio

Founder & CEO

David Johnson

CEO Approval Rating

81/100

Read more
Stay up-to-date with the latest news on VelosBio